Hypera Pharma

Clever Leaves Reports First Quarter 2023 Results

Retrieved on: 
Thursday, May 11, 2023
Workforce, AEBITDA, Leaf, Intellectual property, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., ASC, Partnership, Gateway Group, Hypera Pharma, Financial statement, Sale, Public expenditure, Phase 10, EBITDA, Consolidated financial statement, Traction, Patient, European, RDC, CBD, Growth, Consolidated, Accounting Standards Codification, THC, Video game, Legume, Health care, Pharmaceutical industry, Bank

TOCANCIPÁ, Colombia, May 11, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, is reporting financial and operating results for the first quarter ended March 31, 2023. All financial information is provided in US dollars unless otherwise indicated.

Key Points: 
  • TOCANCIPÁ, Colombia, May 11, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, is reporting financial and operating results for the first quarter ended March 31, 2023.
  • As we move further into 2023, we aim to continue executing on these fronts to drive greater operational efficiency and enhance our positioning within the global cannabinoid supply chain.”
    First Quarter 2023 Summary vs.
  • Additionally, Clever Leaves expects approximately $0.5 million to $0.7 million of annual capital expenditures in 2023, representing an estimated 50% reduction compared to 2022.
  • Clever Leaves will conduct a conference call today at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2023.

Clever Leaves Expands Presence in Brazil Through Partnership with Hypera Pharma

Retrieved on: 
Tuesday, April 18, 2023
Diversified Specialty Institute Holdings, Inc., Partnership, Pharmacy, Hypera Pharma, Research, Patient, Patient safety, RDC, CBD, Growth, Pharmaceutical industry

Hypera Pharma is one of Brazil’s largest pharmaceutical companies in net sales with expertise in the registration, commercialization, and distribution of prescription medicines as well as over-the-counter and skin care products.

Key Points: 
  • Hypera Pharma is one of Brazil’s largest pharmaceutical companies in net sales with expertise in the registration, commercialization, and distribution of prescription medicines as well as over-the-counter and skin care products.
  • Clever Leaves’ leadership position in the region makes it uniquely equipped to enter and thrive in the Brazilian market, meeting all the regulatory and product quality requirements.
  • The CBD products manufactured under this partnership have been registered under RDC 327 framework and are already being sold into distribution channels such as pharmacies and drugstores.
  • “Hypera Pharma’s history, innovative vision, capabilities, focus on high-quality, and commitment to sustainable growth is aligned with Clever Leaves’ values, making them an ideal partner to promote and scale patient access to safe, pharmaceutical-grade cannabis products in Brazil.

Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

Retrieved on: 
Friday, January 29, 2021
Biotechnology, Pharmaceutical, Health, Companies, Takeda Pharmaceutical Company, Economy of Japan, Takeda, Hypera Pharma

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. (Hypera Pharma) for a total value of $825 million USD.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. (Hypera Pharma) for a total value of $825 million USD.
  • The products, while addressing key patient needs in these countries, are outside of the business areas Takeda has designated as core to its global long-term growth.
  • As part of a manufacturing and supply agreement, Takeda will continue to exclusively manufacture the divested products.
  • In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.

Hypera Pharma Switches to Rimini Street Support for Its SAP Applications

Retrieved on: 
Tuesday, October 20, 2020
Data management, Health, Technology, Software, Networks, Pharmaceutical, Internet, Computer companies, Business, Companies, ERP software, SAP SE, Business software, OpenTravel Alliance, SAP, Societates Europaeae, BusinessObjects, Hypera Pharma, Oracle Corporation

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Hypera Pharma, Brazils largest pharmaceutical company, has switched from SAP to Rimini Street Support for its highly customized SAP ECC 6.0 applications, Microsoft SQL Server Database and SAP BusinessObjects software.

Key Points: 
  • Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Hypera Pharma, Brazils largest pharmaceutical company, has switched from SAP to Rimini Street Support for its highly customized SAP ECC 6.0 applications, Microsoft SQL Server Database and SAP BusinessObjects software.
  • View the full release here: https://www.businesswire.com/news/home/20201020005451/en/
    Hypera Pharma Switches to Rimini Street Support for its SAP Applications (Photo: Business Wire)
    Based in So Paulo, Hypera Pharma produces popular medicine brands used by over 200 million Brazilians, along with vitamins, nutritional supplements and dermo cosmetics.
  • Hypera Pharma was using some components of SAP Solution Manager, but working with Rimini Streets Proactive Support Services team, the company instead implemented Rimini Street Watch for SAP .
  • Rimini Street is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

Takeda Continues Divestiture Strategy with Sale of Select OTC and Non-Core Assets in Europe to Orifarm for Up to Approximately $670M USD

Retrieved on: 
Friday, April 24, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Companies, Pharmaceutical companies, Novartis, Life sciences, Hypera Pharma

This transaction represents the continued execution of our strategy to simplify our portfolio and accelerate deleveraging.

Key Points: 
  • This transaction represents the continued execution of our strategy to simplify our portfolio and accelerate deleveraging.
  • Takeda announced last month the sale of non-core products in Latin America to Hypera Pharma for $825 million USD.
  • In July 2019, Takeda completed the sale of Xiidra to Novartis for up to $5.3 billion USD.
  • Orifarm will pay approximately $505 million USD to Takeda in cash at closing, and approximately $70 million USD in non-contingent cash to be paid within four years post-closing.

Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD

Retrieved on: 
Monday, March 2, 2020
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Hypera Pharma, Companies, Industry in Brazil, Economy of Brazil

At the same time, we are confident that Hypera Pharma is well placed to provide patients with uninterrupted access to the products they will acquire.

Key Points: 
  • At the same time, we are confident that Hypera Pharma is well placed to provide patients with uninterrupted access to the products they will acquire.
  • This is Takedas fifth divestment over the last 12 months, contributing to the Companys goal to divest approximately $10 billion USD in non-core assets.
  • Takeda and Hypera Pharma have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture these products and supply them to Hypera Pharma.
  • In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.